Regulatory authorities are tightening safety warnings for gabapentinoids, benzodiazepines and so-called z-drugs so that the known risks of these drugs are more clearly communicated. The drugs are commonly used for neuropathic pain, anxiety and insomnia, and are used by more than a million patients. According to the MHRA, the labeling on the packaging up to now did not adequately express the risk of addiction, habituation and withdrawal from these medicines. Newly, the packaging will have a mandatory warning statement that the drugs "can cause dependence, habituation and withdrawal reactions". Written information for patients is being updated to include clearer definitions of addiction and habit. The leaflets will also provide clearer instructions on how to safely taper and stop treatment. The changes also include information to support open communication between patients and health professionals about the risks of these drugs.